We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
Lapatinib
From Proteopedia
Pharmacokinetics
| Tyrosine Kinase Inhibitor Pharmacokinetics [1] | |||||
|---|---|---|---|---|---|
| Parameter | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Tmax (hr) | 4 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Cmax (ng/ml) | 115 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Bioavailability (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Protein Binding (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| T1/2 (hr) | 9.6 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| AUC (ng/ml/hr) | 1429 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| IC50 (nM) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Dosage (mg) | 100 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Metabolism | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
